MabPlex
Yantai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese CDMO providing end-to-end development and manufacturing services for antibody-based therapeutics.
OncologyImmunologyMetabolic
Technology Platform
An integrated biologics CDMO platform offering cell line development, process optimization, and GMP manufacturing for mAbs and other complex proteins.
Opportunities
Benefiting from the rapid growth of China's biopharma industry and the trend of outsourcing manufacturing.
Risk Factors
Client concentration risk and potential overcapacity in the Chinese CDMO market leading to price erosion.
Competitive Landscape
Competes with global CDMOs like Lonza and Samsung Biologics, as well as other Chinese players like WuXi Biologics and JHL Biotech.